ACADIA Pharmaceuticals Announces Appointment of Terrence Moore as Executive Vice President and Chief Commercial Officer

  ACADIA Pharmaceuticals Announces Appointment of Terrence Moore as Executive
  Vice President and Chief Commercial Officer

Business Wire

SAN DIEGO -- August 19, 2013

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, announced the
appointment of Terrence Moore as Executive Vice President and Chief Commercial
Officer, effective today.Mr. Moore reports to ACADIA’s Chief Executive
Officer, Uli Hacksell, Ph.D., and will be responsible for leading ACADIA’s
commercial activities.

“Terry is an exceptional individual who brings a wealth of commercial
experience to ACADIA from a variety of senior roles at several leading
pharmaceutical companies. He has made key contributions to the building of
multi-billion dollar brands in the CNS field, including Prozac^®, Zyprexa^®,
Risperdal^®, and Effexor XR^®,” said Dr. Hacksell. “Terry’s marketing
expertise and demonstrated ability to execute will help position ACADIA for
success in the planned launch of pimavanserin in Parkinson’s disease psychosis
and for effective life cycle management in order to maximize pimavanserin’s
commercial potential.”

Mr. Moore has more than 25 years of experience as a senior member of sales and
marketing teams at several pharmaceutical companies. Most recently, Mr. Moore
was a principal of Cook-Moore Consulting and, before founding the firm, served
as Vice President at Transcept Pharmaceuticals, where he was responsible for
commercial strategy, business development and commercial alliance activities.
Previously, Mr. Moore served as Vice President, U.S. Head of Neuroscience
Marketing at Organon BioSciences and was responsible for the creation and
building of its Neuroscience Business Unit. He also served as Vice President,
U.S. Marketing, Effexor XR^®, as well as Vice President, Global Strategy
Depression Portfolio at Wyeth Pharmaceuticals. Earlier, Mr. Moore held senior
management positions at Johnson & Johnson, where he helped to launch
Risperdal^® for additional indications in the U.S., and at Eli Lilly, where he
held various sales and marketing roles over 11 years, including Zyprexa^®
Brand Manager.

Mr. Moore holds a B.S. degree in Pharmacy from the University of Florida, a
B.A. degree in Chemistry from the University of South Florida and has
completed executive development programs at the Kellogg School of Management
and Wharton School of Business.

“I am very pleased to be joining an organization dedicated to meeting the
needs of patients suffering from neurological disorders and those who are
responsible for providing their care,” said Mr. Moore. “It is an exciting time
at ACADIA as the company advances toward an NDA submission for pimavanserin
and accelerates its pre-commercial activities. I look forward to working with
the ACADIA team to achieve the goal of bringing this innovative product to
market and building a successful pimavanserin franchise."

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on innovative treatments that
address unmet medical needs in neurological and related central nervous system
disorders. ACADIA has a pipeline of product candidates led by pimavanserin,
which is in Phase III development as a potential first-in-class treatment for
Parkinson's disease psychosis. ACADIA also has clinical-stage programs for
chronic pain and glaucoma in collaboration with Allergan, Inc. and two
advanced preclinical programs directed at Parkinson’s disease and other
neurological disorders. All product candidates are small molecules that
emanate from discoveries made at ACADIA. ACADIA maintains a website at
www.acadia-pharm.com to which ACADIA regularly posts copies of its press
releases as well as additional information and through which interested
parties can subscribe to receive email alerts.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature
are forward-looking statements. These statements include but are not limited
to statements related to the progress and timing of ACADIA’s drug discovery
and development programs, either alone or with a partner, including clinical
trials, the benefits to be derived from ACADIA’s product candidates, including
pimavanserin, the timing of an NDA submission for pimavanserin, the timing of
pre-commercial and commercial activities, the expected contributions of Mr.
Moore to ACADIA’s business, the success of any launch, the life cycle
management or commercial potential of pimavanserin, or the ability to create a
pimavanserin franchise. These statements are only predictions based on current
information and expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected in any of
such statements due to various factors, including the risks and uncertainties
inherent in drug discovery, development and commercialization, and
collaborations with others, building and maintaining a commercial organization
and the fact that past results of clinical trials may not be indicative of
future trial results. For a discussion of these and other factors, please
refer to ACADIA’s annual report on Form 10-K for the year ended December31,
2012 as well as ACADIA’s subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. This
caution is made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. All forward-looking statements are qualified in
their entirety by this cautionary statement and ACADIA undertakes no
obligation to revise or update this press release to reflect events or
circumstances after the date hereof, except as required by law.

Contact:

ACADIA Pharmaceuticals Inc.
Uli Hacksell, Ph.D., Chief Executive Officer
Lisa Barthelemy, Director of Investor Relations
(858) 558-2871
 
Press spacebar to pause and continue. Press esc to stop.